Skip to main content Skip to search Skip to main navigation

ICH: Assembly Meeting 2025

The ICH Assembly met on 18–19 November 2025 in Singapore and welcomed NAFDAC (Nigeria) and SAHPRA (South Africa) as new members, along with two new observers. Elections were held for leadership roles across the Assembly, Management Committee, and MedDRA Steering Committee.

Several major guidelines reached Step 4, including:

  • M11 CeSHarP (harmonized electronic clinical protocol)
  • E2D(R1) on post-approval safety data reporting
  • M14 on RWD-based pharmacoepidemiology studies

Three important draft guidelines entered Step 2b public consultation:

  • E22 (Patient Preference Studies)
  • Q3E (Extractables & Leachables)
  • E20 (Adaptive Clinical Trial Designs)

MedDRA is now available in 27 languages, and the new LMS shows strong uptake. ICH also introduced a new training strategy, including the use of AI tools.

Five experts received the ICH Award 2025 for outstanding contributions. To mark 35 years of ICH, a new communication campaign and an official LinkedIn account were launched. The next Assembly meeting will take place in June 2026 in Rio de Janeiro.


Source:

ICH: Press release, ICH Assembly Meeting, Singapore, November 2025

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
Human Resource Management as a Key to Success

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

Read more
EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

Read more
EMA: Discussions on the Revised ERA Guideline

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.
Read more
Previous
Next